AU2021212258B2 - Amorphous nilotinib microparticles and uses thereof - Google Patents

Amorphous nilotinib microparticles and uses thereof

Info

Publication number
AU2021212258B2
AU2021212258B2 AU2021212258A AU2021212258A AU2021212258B2 AU 2021212258 B2 AU2021212258 B2 AU 2021212258B2 AU 2021212258 A AU2021212258 A AU 2021212258A AU 2021212258 A AU2021212258 A AU 2021212258A AU 2021212258 B2 AU2021212258 B2 AU 2021212258B2
Authority
AU
Australia
Prior art keywords
nilotinib
asd
pharmaceutical composition
fasted
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021212258A
Other languages
English (en)
Other versions
AU2021212258A1 (en
Inventor
Tzehaw CHEN
Daren GEYEN
Joseph MCTARSNEY
Justin SCANLAN
Doua Thao
Christian F. Wertz
Yia YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flex Pharma LLC
Original Assignee
Flex Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flex Pharma LLC filed Critical Flex Pharma LLC
Publication of AU2021212258A1 publication Critical patent/AU2021212258A1/en
Assigned to FLEX PHARMA, LLC reassignment FLEX PHARMA, LLC Amend patent request/document other than specification (104) Assignors: NANOCOPOEIA, LLC
Application granted granted Critical
Publication of AU2021212258B2 publication Critical patent/AU2021212258B2/en
Priority to AU2026204369A priority Critical patent/AU2026204369A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Dental Preparations (AREA)
  • Paints Or Removers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021212258A 2020-01-31 2021-01-29 Amorphous nilotinib microparticles and uses thereof Active AU2021212258B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026204369A AU2026204369A1 (en) 2020-01-31 2026-06-05 Amorphous nilotinib microparticles and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062968749P 2020-01-31 2020-01-31
US62/968,749 2020-01-31
PCT/US2021/015864 WO2021155254A1 (en) 2020-01-31 2021-01-29 Amorphous nilotinib microparticles and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026204369A Division AU2026204369A1 (en) 2020-01-31 2026-06-05 Amorphous nilotinib microparticles and uses thereof

Publications (2)

Publication Number Publication Date
AU2021212258A1 AU2021212258A1 (en) 2022-09-29
AU2021212258B2 true AU2021212258B2 (en) 2026-03-05

Family

ID=74759481

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021212258A Active AU2021212258B2 (en) 2020-01-31 2021-01-29 Amorphous nilotinib microparticles and uses thereof
AU2026204369A Pending AU2026204369A1 (en) 2020-01-31 2026-06-05 Amorphous nilotinib microparticles and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026204369A Pending AU2026204369A1 (en) 2020-01-31 2026-06-05 Amorphous nilotinib microparticles and uses thereof

Country Status (7)

Country Link
US (6) US11389450B2 (cg-RX-API-DMAC7.html)
EP (1) EP4096791A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023513045A (cg-RX-API-DMAC7.html)
AU (2) AU2021212258B2 (cg-RX-API-DMAC7.html)
CA (2) CA3313023A1 (cg-RX-API-DMAC7.html)
IL (1) IL295007A (cg-RX-API-DMAC7.html)
WO (1) WO2021155254A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
CN112294971B (zh) * 2020-02-20 2022-02-01 深圳市泰力生物医药有限公司 具有改进的溶解性的尼洛替尼组合物
EP4221690A4 (en) 2020-09-29 2024-10-30 Shenzhen Pharmacin Co., Ltd. PHARMACEUTICAL COMPOSITIONS
CA3202761A1 (en) 2020-11-25 2022-06-02 Nanocopoeia, Llc Amorphous cabozantinib particles and uses thereof
WO2025099249A1 (en) * 2023-11-08 2025-05-15 Xspray Pharma Ab Pharmaceutical compositions comprising nilotinib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013105894A1 (en) * 2012-01-13 2013-07-18 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
WO2016016665A1 (en) * 2014-08-01 2016-02-04 Hovione International Ltd A method of preparing amorphous solid dispersion in submicron range by co-precipitation

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
GB9504201D0 (en) 1995-03-02 1995-04-19 Scherer Ltd R P Process for the preparation of a solid pharmaceutical dosage form
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6433154B1 (en) 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
FR2766089B1 (fr) 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
PT1121103E (pt) 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
AU2001261625B2 (en) 2000-05-16 2006-04-06 Regents Of The University Of Minnesota High mass throughput particle generation using multiple nozzle spraying
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
EP1401503B1 (en) 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
CN1688291A (zh) 2002-02-01 2005-10-26 辉瑞产品公司 含有固体药物分散体的即刻释放剂型
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US20050112196A1 (en) 2003-10-07 2005-05-26 Jianbo Xie Rapidly disintegrating formulation
EP1753402B1 (en) 2004-05-28 2008-10-01 Pfizer Products Incorporated Pharmaceutical compositions with enhanced performance comprising a hpmca polymer
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
WO2007089883A2 (en) 2006-01-31 2007-08-09 Nanocopoeia, Inc. Nanoparticle coating of surfaces
CA2637883C (en) 2006-01-31 2015-07-07 Regents Of The University Of Minnesota Electrospray coating of objects
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2008055966A1 (en) 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
US9040816B2 (en) 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
TWI547282B (zh) 2007-07-02 2016-09-01 愛戴爾製藥股份有限公司 樂命達之口服分解錠劑組合物
WO2009010837A2 (en) 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
US8992471B2 (en) 2007-11-05 2015-03-31 Nanocopoeia, Inc. Coated devices and method of making coated devices that reduce smooth muscle cell proliferation and platelet activity
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP2254556A2 (en) 2008-03-11 2010-12-01 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
GB0816365D0 (en) * 2008-09-08 2008-10-15 Univ Belfast Polymeric material
CZ20098A3 (cs) 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
WO2011026080A1 (en) 2009-08-31 2011-03-03 Wilmington Pharmaceuticals, Llc Fast disintegrating compositions of meloxicam, processes for preparation, and use to treat arthritis and/or pain
EP3566697B1 (en) 2009-11-09 2024-09-11 Wyeth LLC Tablet formulations of neratinib maleate
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
RU2566716C2 (ru) 2010-06-09 2015-10-27 Эббви Бахамаз Лтд. Твердые дисперсии, содержащие ингибиторы киназ
JP6073788B2 (ja) 2010-09-14 2017-02-01 ナノロジカ アクティエボラーグ 難水溶性医薬及び化粧品有効成分のための過飽和送達媒体
EP2665559B1 (en) 2011-01-19 2018-07-18 Washington University Electrohydrodynamic atomization nozzle emitting a liquid sheet
IN2011CH01887A (cg-RX-API-DMAC7.html) 2011-06-02 2012-12-14
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
JP6062442B2 (ja) 2011-10-13 2017-01-18 ジェネンテック, インコーポレイテッド 薬剤誘発性低酸症の治療
US9301957B2 (en) 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
HRP20210237T1 (hr) 2012-01-13 2021-03-19 Xspray Microparticles Ab Postupak za proizvodnju stabilnih, amorfnih hibridnih nanočestica koje sadrže barem jedan inhibitor proteinske kinaze i barem jedan polimerni sastojak koji stabilizira i tvori matricu
US20130274342A1 (en) 2012-04-12 2013-10-17 Cerecor, Inc. Compositions and methods for treating cough
US10195150B2 (en) 2012-12-20 2019-02-05 Kashiv Pharma, Llc Orally disintegrating tablet formulation for enhanced bioavailability
TW201446286A (zh) 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
EP3102188A4 (en) 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
MX2016010213A (es) 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
HU231013B1 (hu) 2014-05-26 2019-11-28 Egis Gyógyszergyár Zrt. Dasatinib sók
US20150110871A1 (en) 2014-06-02 2015-04-23 David Wong Gastric retentive tablet compositions
CA2965157A1 (en) 2014-11-25 2016-06-02 Nanocopoeia, Llc Method of converting a crystalline compound to an amorphous compound, method of increasing the solubility of a crystalline compound in a biorelevant fluid, and nanoparticles that achieve supersaturation
WO2016097011A1 (en) 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising amorphous nilotinib
US20160175881A1 (en) 2014-12-22 2016-06-23 Nanocopoeia, Llc Electrospray methods, electrospray systems, and methods of forming crystalline particles
JP6513702B2 (ja) 2014-12-25 2019-05-15 株式会社ダイセル 超速崩壊錠剤及びその製造方法
WO2016118515A1 (en) 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
PT108368B (pt) 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
JP2018517734A (ja) 2015-06-17 2018-07-05 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー デフェラシロクスの改善された製剤およびその作製方法
BR112017013253A2 (pt) 2015-07-27 2018-02-27 Unichem Laboratories Limited comprimidos de desintegração oral, processo para produzir comprimido de desintegração oral contendo tofacitinibe ou seus sais farmaceuticamente aceitáveis, processo para produzir comprimido de desintegração oral, desintegrante, e edulcorantes
WO2017064538A1 (en) 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018078392A1 (en) 2016-10-29 2018-05-03 Cipla Limited Polymorphs of dasatinib
EP3705118B1 (en) 2017-10-31 2024-02-14 Samyang Holdings Corporation Oral solid dosage form composition having improved disintegration and preparation method therefor
WO2019151405A1 (ja) 2018-02-02 2019-08-08 ニプロ株式会社 錠剤及びその製造方法
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
ES2993251T3 (en) * 2019-02-18 2024-12-26 Slayback Pharma Llc Pharmaceutical compositions of nilotinib
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
US20230058417A1 (en) * 2020-02-06 2023-02-23 Briggs & Stratton, Llc Battery pack for battery powered equipment
US20220378788A1 (en) 2020-04-30 2022-12-01 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013105894A1 (en) * 2012-01-13 2013-07-18 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
WO2016016665A1 (en) * 2014-08-01 2016-02-04 Hovione International Ltd A method of preparing amorphous solid dispersion in submicron range by co-precipitation

Also Published As

Publication number Publication date
WO2021155254A1 (en) 2021-08-05
AU2026204369A1 (en) 2026-06-25
US20220362246A1 (en) 2022-11-17
JP2026053379A (ja) 2026-03-25
US11998548B2 (en) 2024-06-04
US20230172931A1 (en) 2023-06-08
US20230158026A1 (en) 2023-05-25
US12029740B2 (en) 2024-07-09
US20230181585A1 (en) 2023-06-15
CA3168680A1 (en) 2021-08-05
US20250032491A1 (en) 2025-01-30
CA3313023A1 (en) 2026-06-21
US20210267975A1 (en) 2021-09-02
JP2023513045A (ja) 2023-03-30
EP4096791A1 (en) 2022-12-07
AU2021212258A1 (en) 2022-09-29
IL295007A (en) 2022-09-01
US12053471B2 (en) 2024-08-06
US11389450B2 (en) 2022-07-19
US12016861B2 (en) 2024-06-25

Similar Documents

Publication Publication Date Title
US11633398B2 (en) Amorphous solid dispersions of dasatinib and uses thereof
US11998548B2 (en) Amorphous nilotinib microparticles and uses thereof
US11559485B2 (en) Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US12564584B2 (en) Amorphous cabozantinib particles and uses thereof
US20220378788A1 (en) Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: FLEX PHARMA, LLC

Free format text: FORMER NAME(S): NANOCOPOEIA, LLC

FGA Letters patent sealed or granted (standard patent)